The present invention relates to compounds according to general formula (I)

##STR00001##

which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

The present invention relates to compounds according to general formula (I)

##STR00001##

which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

The disclosure includes compounds of Formula (A) wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11, h, j, m, n, k, v, s, g, V, W, L, Z.sub.1, Q.sub.1, Q.sub.2, Q.sub.3, Q.sub.4, Q.sub.5, Q.sub.6, and Q.sub.7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

##STR00001##

The disclosure includes compounds of Formula (A) wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11, h, j, m, n, k, v, s, g, V, W, L, Z.sub.1, Q.sub.1, Q.sub.2, Q.sub.3, Q.sub.4, Q.sub.5, Q.sub.6, and Q.sub.7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

##STR00001##

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:

##STR00001##

where A, B, R.sub.1, X.sub.1, X.sub.2, and W are described herein.

An organic compound is represented by general formula (1) below: ##STR00001## where X.sub.1 and X.sub.2 are each independently selected from the group consisting of an alkyl group, an aryl group, and an aralkyl group; R.sub.11 to R.sub.16 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a heterocyclic group, and a halogen atom; R.sub.21 and R.sub.22 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an aryl group, and an aralkyl group; and A.sub.1.sup.− and A.sub.2.sup.− each independently represent a monovalent anion.

An organic compound is represented by general formula (1) below: ##STR00001## where X.sub.1 and X.sub.2 are each independently selected from the group consisting of an alkyl group, an aryl group, and an aralkyl group; R.sub.11 to R.sub.16 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a heterocyclic group, and a halogen atom; R.sub.21 and R.sub.22 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an aryl group, and an aralkyl group; and A.sub.1.sup.− and A.sub.2.sup.− each independently represent a monovalent anion.

The present invention includes a novel series of host materials for OLEDs based on substituted fused 1,2,4-triazines, represented by Formula I. The invention also includes an organic light-emitting device comprising an anode, a cathode, and an organic layer, disposed between the anode and the cathode, comprising a compound of Formula I. The compounds of the invention may improve the device EQE and lifetime. ##STR00001##

The present invention includes a novel series of host materials for OLEDs based on substituted fused 1,2,4-triazines, represented by Formula I. The invention also includes an organic light-emitting device comprising an anode, a cathode, and an organic layer, disposed between the anode and the cathode, comprising a compound of Formula I. The compounds of the invention may improve the device EQE and lifetime. ##STR00001##

The present disclosure relates to novel, scalable methods of making substituted tricyclic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject.